NASDAQ:ENTX Entera Bio (ENTX) Stock Price, News & Analysis $1.82 +0.02 (+1.11%) Closing price 04:00 PM EasternExtended Trading$1.84 +0.02 (+0.88%) As of 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Entera Bio Stock (NASDAQ:ENTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Entera Bio alerts:Sign Up Key Stats Today's Range$1.76▼$1.8950-Day Range$1.73▼$2.1352-Week Range$1.50▼$2.79Volume114,210 shsAverage Volume105,084 shsMarket Capitalization$82.72 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingBuy Company Overview Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. Read More Entera Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreENTX MarketRank™: Entera Bio scored higher than 39% of companies evaluated by MarketBeat, and ranked 690th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEntera Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageEntera Bio has received no research coverage in the past 90 days.Read more about Entera Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Entera Bio are expected to decrease in the coming year, from ($0.28) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entera Bio is -7.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entera Bio is -7.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntera Bio has a P/B Ratio of 8.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Entera Bio's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.08% of the outstanding shares of Entera Bio have been sold short.Short Interest Ratio / Days to CoverEntera Bio has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Entera Bio has recently decreased by 32.37%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEntera Bio does not currently pay a dividend.Dividend GrowthEntera Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.08% of the outstanding shares of Entera Bio have been sold short.Short Interest Ratio / Days to CoverEntera Bio has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Entera Bio has recently decreased by 32.37%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 1 people have searched for ENTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Entera Bio insiders have not sold or bought any company stock.Percentage Held by Insiders10.38% of the stock of Entera Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 14.11% of the stock of Entera Bio is held by institutions.Read more about Entera Bio's insider trading history. Receive ENTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTX Stock News HeadlinesEntera Bio Announces Second Quarter 2025 Financial Results and Business Updates2 hours ago | globenewswire.comEntera Bio stock surges after FDA agrees on BMD endpoint for EB613July 28, 2025 | investing.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.August 8 at 2:00 AM | Brownstone Research (Ad)Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with OsteoporosisJuly 28, 2025 | globenewswire.comEntera Bio Stock Price, Quotes and Forecasts | NASDAQ:ENTX | BenzingaJune 6, 2025 | benzinga.comEntera Bio Reports Q1 2025 Financial Results and Strategic DevelopmentsMay 16, 2025 | tipranks.comEntera Bio Ltd.: Entera Bio Announces First Quarter 2025 Financial Results and Business UpdatesMay 10, 2025 | finanznachrichten.deEntera Bio Announces First Quarter 2025 Financial Results and Business UpdatesMay 9, 2025 | globenewswire.comSee More Headlines ENTX Stock Analysis - Frequently Asked Questions How have ENTX shares performed this year? Entera Bio's stock was trading at $2.12 on January 1st, 2025. Since then, ENTX stock has decreased by 13.2% and is now trading at $1.84. How were Entera Bio's earnings last quarter? Entera Bio Ltd. (NASDAQ:ENTX) posted its earnings results on Friday, May, 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The company had revenue of $0.04 million for the quarter. Entera Bio had a negative trailing twelve-month return on equity of 95.10% and a negative net margin of 4,525.11%. When did Entera Bio IPO? Entera Bio (ENTX) raised $11 million in an initial public offering on Thursday, June 28th 2018. The company issued 1,400,000 shares at a price of $8.00 per share. Maxim Group acted as the underwriter for the IPO and Joseph Gunnar was co-manager. Who are Entera Bio's major shareholders? Entera Bio's top institutional investors include Bessemer Group Inc. (0.31%). Insiders that own company stock include Miranda Jayne Toledano, Sean Ellis and Haya Taitel. View institutional ownership trends. How do I buy shares of Entera Bio? Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Entera Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Entera Bio investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY) and GE Aerospace (GE). Company Calendar Last Earnings5/09/2025Today8/08/2025Next Earnings (Estimated)8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ENTX CIK1638097 Webwww.enterabio.com Phone(722) 532-7151FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Entera Bio$10.00 High Price Target$10.00 Low Price Target$10.00 Potential Upside/Downside+440.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($0.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.54 million Net Margins-4,525.11% Pretax Margin-4,518.83% Return on Equity-95.10% Return on Assets-82.77% Debt Debt-to-Equity RatioN/A Current Ratio13.07 Quick Ratio13.07 Sales & Book Value Annual Sales$180 thousand Price / Sales467.13 Cash FlowN/A Price / Cash FlowN/A Book Value$0.23 per share Price / Book8.04Miscellaneous Outstanding Shares45,450,000Free Float40,734,000Market Cap$84.08 million OptionableOptionable Beta1.52 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:ENTX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entera Bio Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entera Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.